清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Real-world progression in the survival of de novo Metastatic prostate cancer over the past decade

前列腺癌 医学 比例危险模型 内科学 相对存活率 总体生存率 肿瘤科 生存分析 癌症 多元分析 转移 癌症登记处
作者
Xiaoxiao Guo,Haoran Xia,Fengbo Zhang,Gangyue Hao
出处
期刊:Urologic Oncology-seminars and Original Investigations [Elsevier]
标识
DOI:10.1016/j.urolonc.2023.11.021
摘要

The impact of evolving treatment strategies for metastatic prostate cancer (mPCa) on real-world survival is not well understood. We analyzed changes in mPCa survival over the past decade and discussed the potential driving factors behind these changes. Our study involved 43,228 mPCa patients (2004–2020) from the SEER database, divided into 4 diagnostic periods. We used a multivariate Cox proportional hazards model to evaluate diagnostic periods' influence on overall mortality (OM) and prostate cancer-specific mortality (PSM), and calculated relative median survival improvements between adjacent periods. Subgroup analyses based on age and distant metastasis sites were conducted. Patients diagnosed in 2016 to 2020 experienced significantly reduced mortality risk compared to those in 2004 to 2007 (HR 0.64 for OM, HR 0.62 for CSM, both P < 0.001). The study period witnessed an absolute improvement in median overall survival (OS) and prostate cancer-specific survival (PCSS), 17 months (54.8%) and 25 months (67.6%) respectively. The most rapid relative survival improvement occurred post-2016, with a 29.7% increase in median OS and a 37.8% increase in PCSS compared to 2012 to 2015. There was a significant reduction in mortality risk throughout the study period in both age groups (age <75 and ≥75), but absolute survival gains were smaller in the older group (24 months [68.6%] vs. 8 months [32%] for OS, 36 months [90.0%] vs. 11 months [33.3%] for PCSS), with lower relative survival improvements after 2016 (37.2% vs. 17.9% for OS, 49% vs. 22.2% for PCSS). All metastasis site subgroups (except M1a) exhibited a significant reduction in mortality risk (all P < 0.001). Absolute survival improvements were 58 months (134.9%) for M1a, 16 months (50.0%) for M1b, and 17 months (54.8%) for M1c. The survival of mPCa have significantly improved over the past decade, although the progress is slower in elderly patients. Investigating the underlying reasons for survival differences among various patient profiles can further refine mPCa treatment strategies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
婷婷完成签到 ,获得积分10
42秒前
Richard完成签到 ,获得积分10
55秒前
zai完成签到 ,获得积分20
1分钟前
小小猪完成签到,获得积分10
1分钟前
2分钟前
baobeikk完成签到,获得积分10
2分钟前
chloe完成签到,获得积分10
2分钟前
2分钟前
2分钟前
科研通AI2S应助科研通管家采纳,获得10
2分钟前
3分钟前
CC发布了新的文献求助20
3分钟前
4分钟前
TongMan发布了新的文献求助10
4分钟前
Ava应助TongMan采纳,获得10
4分钟前
jyy应助科研通管家采纳,获得10
4分钟前
小白完成签到 ,获得积分10
4分钟前
楚襄谷完成签到 ,获得积分10
5分钟前
al完成签到 ,获得积分10
5分钟前
123完成签到 ,获得积分10
6分钟前
6分钟前
ZL完成签到 ,获得积分10
8分钟前
青梅发布了新的文献求助10
8分钟前
8R60d8应助MAC采纳,获得10
9分钟前
10分钟前
10分钟前
黑眼豆豆完成签到,获得积分10
11分钟前
12分钟前
12分钟前
内含子发布了新的文献求助10
12分钟前
学习使勇哥进步完成签到 ,获得积分10
12分钟前
12分钟前
12分钟前
内含子完成签到,获得积分10
12分钟前
vbnn完成签到 ,获得积分10
13分钟前
badgerwithfisher完成签到,获得积分10
13分钟前
1437594843完成签到 ,获得积分10
13分钟前
14分钟前
meng发布了新的文献求助10
14分钟前
Billy应助科研通管家采纳,获得30
14分钟前
高分求助中
The late Devonian Standard Conodont Zonation 2000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
Very-high-order BVD Schemes Using β-variable THINC Method 890
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 800
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3257020
求助须知:如何正确求助?哪些是违规求助? 2899025
关于积分的说明 8303370
捐赠科研通 2568282
什么是DOI,文献DOI怎么找? 1395014
科研通“疑难数据库(出版商)”最低求助积分说明 652925
邀请新用户注册赠送积分活动 630664